Highest-materiality recent filing
RxSight Q2 revenue $33.7M, product sales down 19% YoY; withdraws 2026 guidance
Product sales $27.2M (-19% YoY); LAL units 24,917; LDD units 12.
RxSight appoints Aziz Mottiwala as CEO; founder Ron Kurtz becomes CMO effective July 20, 2026
Mottiwala receives $750k base salary, 90% target bonus, and $14M in equity ($2M option + $12M RSU).
RxSight receives $60M upfront; potential $70M feasibility milestone, $30M FDA submission milestone, $40M approval milestone.
RxSight lowers FY2026 sales guidance, reports Q2 prelim revenue $32-34M, Alcon collaboration
Preliminary Q2 2026 revenue $32-34M, including $5-7M from Alcon collaboration; sales ~$27M (24,917 LAL units, 11 LDD units).
RxSight Reports Q1 2026 Sales of $30.9M, Net Loss Widens, Reiterates Full-Year Guidance
Q1 2026 sales of $30.9M, down 18.5% YoY, driven by 27,472 Light Adjustable Lens units sold.
RxSight reports Q4 revenue down 19% YoY; 2025 net loss $(38.9M); issues weak 2026 guidance
Q4 2025 revenue $32.6M (-19% YoY); LAL revenue -1%, LDD revenue -72%.
Q4 2025 revenue ~$32.6M; FY2025 revenue ~$134.5M vs prior guidance $125-130M.
RxSight enters CFO transition agreement with Thunen; reaffirms 2025 outlook
Shelley Thunen transitions from CFO; transition and consulting agreements executed effective Dec 23, 2025.
RxSight CFO Shelley Thunen to transition; consulting agreement through Dec 2026
CFO Shelley Thunen to depart by Jan 31, 2026 or upon appointment of successor; will serve as consultant thereafter.
RxSight Q3 revenue down 14% YoY to $30.3M; net loss widens to $9.8M
Revenue $30.3M (-14% YoY); LAL volume up 6% but LDD placements down 68%.
RxSight Q2 revenue $33.6M (-4% YoY); net loss $(11.8)M; reaffirms FY2025 guidance
Total revenue $33.6M, down 4% from $34.9M in Q2 2024; LAL units up 13%, LDD units down 49%.
RxSight preliminary Q2 revenue $33.6M, down 4% YoY; cuts FY2025 guidance to $120-130M
Preliminary Q2 revenue ~$33.6M, down 4% YoY and 11% sequentially; LAL volume +13% YoY, LDD sales -49% YoY.
RxSight Q1 revenue $37.9M (+28% YoY); LAL volume up 36%
Q1 revenue $37.9M (+28% YoY); LAL revenue +37%, LDD revenue +8%.
RxSight preliminary Q1 revenue $37.9M (+28% YoY); cuts FY2025 guidance to $160M-$175M
Preliminary Q1 2025 revenue ~$37.9M, up 28% YoY but down 6% QoQ; LAL procedure volume 27,579 (+36% YoY).
RxSight Q4 revenue $40.2M (+41% YoY), LAL volume +61%; reaffirms FY2025 guidance
Q4 revenue $40.2M (+41% YoY); full-year revenue $139.9M (+57% YoY).
RxSight reports preliminary Q4/FY2024 rev ~$40.2M/$139.9M, +41%/+57% YoY; guides 2025 rev $185-197M
Q4 2024 revenue ~$40.2M (+41% YoY); FY2024 ~$139.9M (+57% YoY).
RxSight Q3 revenue $35.3M (+59% YoY); raises FY revenue guidance to $139-140M
Revenue $35.3M, up 59% YoY; LAL procedures 24,554 (+80%), LDD installed base 888 (+51%).
RxSight Q2 revenue $34.9M, +68% YoY; raises FY2024 guidance above prior range
Revenue $34.9M in Q2 2024, up 68% from $20.8M in Q2 2023; LAL volume +92% to 24,214 lenses.
RxSight prices $100M public stock offering at $56/share for commercial expansion
Offering of 1,785,714 shares at $56/share; underwriters have 30-day option for 267,857 additional shares.
RxSight Q1 revenue $29.5M (+69% YoY), raises FY2024 guidance
LAL volume up 92% to 20,218 units; LDD installed base reaches 732 (+61% YoY).
RxSight Q4 revenue $28.6M (+78% YoY); LAL volume +98% YoY; guides FY2024 rev $128-135M
Q4 2023 revenue $28.6M, up 78% YoY, with 77 LDDs sold and 18,071 LALs (+98% YoY).
RxSight Q4 rev ~$28.6M (+78% YoY); FY2023 rev ~$89.1M (+82%); guides FY2024 rev $128-135M
Q4 2023 rev ~$28.6M (+78% YoY) driven by 77 LDD placements and 18,071 LALs sold.
RxSight Q3 revenue up 76% to $22.2M; raises FY2023 guidance
Q3 revenue $22.2M (+76% YoY); net loss $(12.4)M, EPS $(0.35); adjusted net loss $(6.9)M, adj. EPS $(0.19)
RxSight Q2 revenue $20.8M (+83% YoY); raises FY2023 guidance; pays off $40M debt
Q2 revenue $20.8M (+83% YoY); net loss $(13.8)M vs $(16.7)M last year.
RxSight refinances debt: $20M new loan at lower rate, extends maturity to 2028
Sold 834,748 common shares via ATM for $19.4M net proceeds; used $20M to repay existing debt.
RxSight Q1 revenue $17.5M (+96% YoY); raises FY2023 revenue and margin guidance
Revenue $17.5M, up 96% YoY; gross margin improved to 59% from 42%.
RxSight Q4 revenue $16.1M (+91% YoY); FY22 revenue $49.0M (+117%); guides FY23 rev $78-83M
Q4 2022 revenue $16.1M, up 91% YoY; LAL procedure volumes up 208% to 9,123 units; LDD installed base 400 (+94% YoY).
RxSight prices public offering of 4M shares at $12.50 each for ~$50M gross proceeds
Offering of 4,000,000 shares of common stock at $12.50 per share; gross proceeds ~$50.0M, net ~$46.7M.
RxSight reports preliminary Q4 2022 revenue $16.1M, up 91% YoY; full-year $49.0M, up 117%
Q4 2022 revenue $16.1M (+91% YoY); 57 LDDs sold, installed base 400 LDDs as of Dec 31, 2022.
RxSight Q3 revenue $12.6M (+118% YoY); raises FY22 guidance to $47-48M
Q3 2022 revenue of $12.6M, up 118% YoY; LDD installed base reached 343 units (113% YoY increase).
RxSight Q2 revenue $11.4M (+132% YoY); raises FY22 guidance to $44-46M
Revenue $11.4M (+132% YoY); sold 49 LDDs, installed base 294 (+126% YoY).
RxSight files $200M shelf registration and enters $50M ATM equity offering with BofA
Filed $200M shelf registration on Form S-3 covering common stock, preferred, debt, warrants, and units.
RxSight Q1 revenue up 157% to $8.9M; raises 2022 revenue guidance
Revenue $8.9M (+157% YoY); LDD sales 40 units (+208%), installed base 246 (+134%).
RxSight Q4 revenue $8.4M (+71% YoY); FY22 guidance $40-44M
Q4 2021 revenue $8.4M, up 71% YoY; FY2021 revenue $22.6M, up 54% YoY.
RxSight Q4 revenue ~$8.4M (+71% YoY); full year 2021 revenue ~$22.6M (+54% YoY)
Q4 2021 revenue ~$8.4M, up 71% YoY; sold 45 LDDs (installed base 206) and 2,959 LALs.
RxSight Q3 2021 revenue $5.8M (+39% YoY); net loss $12.7M; FY revenue guidance $21.0-$21.4M
Q3 revenue $5.8M, up 39% YoY and 18% QoQ; 31 LDDs sold, installed base 161.
RxSight Q2 revenue $4.9M (+81% YoY); net loss $(13.5)M; raises ~$120M in July IPO
Revenue $4.9M (+81% YoY); sold 25 LDDs and 1,825 LALs during Q2.
On December 29, 2021 the board of directors (the “Board”) of RxSight, Inc. (the “Company”) increased the number of its authorized directors from seven to nine, and appointed Shweta Singh Maniar and Tamara Fountain, M.D. to fill the two newly created openings on the Board, effective December 31, 2021 and January 1, 2022, respectively.
On December 29, 2021 the board of directors (the “Board”) of RxSight, Inc. (the “Company”) increased the number of its authorized directors from seven to nine, and appointed Shweta Singh Maniar and Tamara Fountain, M.D. to fill the two newly created openings on the Board, effective December 31, 2021 and January 1, 2022, respectively.
Max materiality 0.85 · Median 0.75 · Most common event earnings